Minerals Technologies Inc. (MTX) Stock Price & How to Invest

Minerals Technologies Inc. (NYSE: MTX) is a global specialty minerals company built originally out of Pfizer's minerals unit. It is one of the largest producers of precipitated calcium carbonate (PCC) and the world's largest bentonite producer, and it organizes its business into two segments: Consumer & Specialties (household and personal care products such as cat litter, personal care, fabric care, edible-oil purification, plus specialty additives) at roughly 53% of sales, and Engineered Solutions (high-temperature refractory technologies and environmental and infrastructure products) at roughly 47%. The company sells into paper, packaging, construction, automotive, foundry, steel, and consumer markets across more than 35 countries.

The investment picture is one of a durable, cash-generative industrial trading at a below-market multiple while a legacy overhang gets resolved. Underlying results have held up: second quarter 2026 sales of ~$548 million were up ~3.7% year over year and adjusted EPS came in at ~$1.60, just short of a ~$1.63 consensus. The reported line looks very different, because the talc reserve pushed the quarter to a GAAP net loss of ~$184 million and left trailing twelve month net income at about -$67 million. At ~$63.65 on October 16, 2026, the shares were up ~4% year to date and ~7% over one year, for a market value of ~$2.0 billion. The story remains dominated by talc-related product-liability claims that MTX is channeling into a proposed $450 million trust via the Chapter 11 of subsidiary BMI OldCo, with a large associated charge booked in 2026. Owning MTX is therefore a bet that the underlying minerals franchise keeps compounding modestly while the litigation is capped and removed as an open-ended risk.

The dominant risk is the talc litigation itself: the reorganization plan must be confirmed and funded, and a large charge (around $290 million booked in 2026) already pressures reported results, turning the second quarter into a GAAP net loss of ~$184 million, with the possibility of adverse rulings or higher-than-expected claim funding. As a specialty-minerals maker, MTX is exposed to energy, freight, and raw-material cost inflation, which has recently squeezed margins amid geopolitical disruption. Its end markets (paper, construction, steel, and automotive) are cyclical and sensitive to global industrial demand and currency swings given large international exposure. Competition from larger diversified players such as Imerys and Omya can pressure pricing and share. Refinancing the 5.000% 2028 notes with 7.500% notes due 2032 raises interest cost on that slice of debt. Finally, the modest dividend yield and mid-cap size mean the equity can be volatile around litigation and macro headlines.

4 analysts publish price targets on MTX, averaging $91.25 against a $62.99 price as of October 2026, or +44.9%. The published targets run from $90.00 to $95.00, a narrow spread, and the ratings split 4 buy, 0 hold, 0 sell. Over the last six months there has been 1 raise and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MTX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Minerals Technologies Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Diversified specialty-minerals franchise. MTX spans two segments and many end markets, so no single customer or industry dominates results. The most optimistic published target, $95.00, assumes this works close to its best case.

The case against. The dominant risk is the talc litigation itself: the reorganization plan must be confirmed and funded, and a large charge (around $290 million booked in 2026) already pressures reported results, turning the second quarter into a GAAP net loss of ~$184 million, with the possibility of adverse rulings or higher-than-expected claim funding. The most pessimistic target, $90.00, is roughly what MTX is worth if this bites instead.

Read the full bull and bear case on MTX, including what would have to change to break either one. Walnut is not an investment adviser.

No. Minerals Technologies Inc. (MTX) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Minerals Technologies Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$2.15B
• Q2 2026 revenue: ~$548M (up ~3.7% YoY)
• Q2 2026 adjusted EPS: ~$1.60 (vs ~$1.63 est.)
• Operating margin (TTM): ~13.6%
• Net income (TTM, GAAP): ~-$67M (talc charge)
• Forward P/E: ~9x
• Market cap: ~$2.0B
• Dividend yield: ~0.75%

With the talc charge pushing trailing GAAP earnings negative, there is no meaningful trailing P/E; on forward estimates (~$6.88 of 2027 EPS) MTX trades at roughly 9 times earnings, about 0.9 times sales and ~7 times EV/EBITDA, a clear discount to the broader chemicals and materials group. That discount reflects the market pricing in talc-litigation uncertainty and a slower top line rather than weak operations, since operating margin is ~13.6% and free cash flow over the trailing year was ~$393 million. The valuation gap is still the crux of the debate, and third quarter results around October 29, 2026 will show whether growth reaccelerates from the second quarter's ~3.7%.

Other names that sit close to MTX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MTX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MTX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MTX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

MTX is a steady, mid-cap specialty-minerals maker trading at a discounted multiple, with the talc litigation resolution as the swing factor for how the market re-rates it.

Whether MTX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MTX a buy or a sell?, and where the stock could go from here in the MTX stock forecast.

For income investors, whether MTX pays a dividend and how the payout looks is covered in does MTX pay a dividend? And to weigh MTX against a peer, read the full side-by-side comparisons: MTX vs RHI and MTX vs WDFC.